Advertisement

Topics

Dompé Farmaceutici S.p.A. Company Profile

08:54 EST 12th December 2018 | BioPortfolio

Dompé is one of the most dynamic, flexible and innovative set-ups on the European scene.Successful in the traditional pharmaceutical market in the treatment of respiratory and osteoarticular pathologies, Dompé has also developed its presence in the area of biotechnology with innovative drugs and services
Its objective is to give value to every phase of production, every new research project, every sort of relationship with the Doctor and the Patient.
Flexibility, quality and the capacity for constructive work make Dompé the ideal partner

Location

Via San Martino, 12-12/a
Milano
20122
Italy

Contact

Phone: 39 02 583831
Fax: 39 02 58300590
Email: webmaster@dompe.it


News Articles [15 Associated News Articles listed on BioPortfolio]

Dompé’s Oxervate gets approval to treat neurotrophic keratitis in US

Italian biopharmaceutical company Dompé farmaceutici has secured approval from the US Food and Drug Administration (FDA) for the use of...Read More... The post Dompé’s Oxervate gets approval to tr...

FDA Approves Dompé’s Rare Eye Disease Drug

US regulators have approved the first drug to treat neurotrophic keratitis, a rare degenerative disease that progressively affects the cornea, the clear layer at the front of the eye, eventually leadi...

FDA approves Dompé’s Oxervate to treat neurotrophic keratitis

NK is a rare and progressive eye disease, which may result in corneal scarring and vision loss. The FDA has approved Oxervate eye drops for use in adults The post FDA approves Dompé’s Oxervate to ...

FDA Approves Dompé’s Oxervate for Treatment of Neurotrophic Keratitis, a Rare Eye Disease

MILAN and SAN BRUNO, Calif., Aug. 22, 2018 /PRNewswire/ — Dompé today announced that the U.S. Food and Drug Administration (FDA) has approved OxervateTM (cenegermin-bkbj ophthalmic solution), a...

Dompé gives the FDA its first approved neurotrophic keratitis treatment

Milan-based biotech firm Dompé has revealed that the FDA has awarded approval in the US to its Oxervate (cenegermin-bkbj ophthalmic solution) product in the treatment of neurotrophic keratitis (NK). ...

Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

Protalix to receive $25 million upfront, an additional up to $20 million in development costs and an additional up to $760 million in potential regulatory and commercial milestone payments for the U....

Dompe wins FDA nod for rare eye disease treatment

Dompe Farmaceutici's Oxervate, or cenegermin, was approved by the FDA as a treatment for patients with neurotrophic keratiti -More- 

Fidia Announces Presentation of New Data Evaluating HYMOVIS® (HYADD®4) Effects on Metalloprotease Inhibition at 2018 ACR/ARHP Annual Meeting

Poster (Abstract 2004): “Effective Inhibition of Metalloproteases By a Viscosupplement Based on a Hyaluronic Acid Amide (HYADD®4)” Fidia Farmaceutici S.p.A., a world lead...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Curosurf [Cornerstone Therapeutics Inc.]

CUROSURF (poractant alfa)Intratracheal Suspension

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Phospholipid components of the synthetic pulmonary surfactant CHF5633 probed by fluorescence spectroscopy.

CHF5633 (Chiesi Farmaceutici, Italy) is a synthetic pulmonary surfactant currently under clinical development for the treatment of Respiratory Distress Syndrome in premature infants. The product is co...

Quenching of tryptophan fluorescence in a highly scattering solution: Insights on protein localization in a lung surfactant formulation.

CHF5633 (Chiesi Farmaceutici, Italy) is a synthetic surfactant developed for respiratory distress syndrome replacement therapy in pre-term newborn infants. CHF5633 contains two phospholipids (dipalmit...

Triticum vulgare extract exerts an anti-inflammatory action in two in vitro models of inflammation in microglial cells.

Triticum vulgare has been extensively used in traditional medicine thanks to its properties of accelerating tissue repair. The specific extract of Triticum vulgare manufactured by Farmaceutici Damor (...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Filler Performance on the Nasolabial Folds of Aliaxin® EV With and Without Lidocaine 0.3%

Evaluation of the filler performance on the nasolabial folds of Aliaxin® EV with and without lidocaine 0.3%: comparison within subjects (half face method)

Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)

Aim of the study is to evaluate the re-volumizing performance and the duration effect of the product Aliaxin (new trademark) in women aged 40-65 years with midface volume defects due to ag...

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

Early Viscosupplementation After Partial Meniscectomy: a Randomized Controlled Trial

The rational of intra-articular viscosupplementation is based on both the biological and mechanical properties of HA, which exerts positive effects on the modulation of the entire joint en...

Companies [7 Associated Companies listed on BioPortfolio]

Dompé Farmaceutici S.p.A.

Dompé is one of the most dynamic, flexible and innovative set-ups on the European scene.Successful in the traditional pharmaceutical market in the treatment of respiratory and osteoarticular patholog...

Fidia Farmaceutici

Fidia Farmaceutici is part of Fidia Pharma Group, an Italian multinational company, with R&D, manufacturing and sales capabilities, and an extensive product portfolio mainly based...

ViRexx Medical

ViRexx Medical Corp. is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and chronic viral infections. ViRexx's mos...

Fidia Farmaceutici S.p.A.

Fidia Farmaceutici is part of Fidia Pharma Group, an Italian multinational company, with R&D, manufacturing and sales capabilities, and an extensive product portfolio mainly based...

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

More Information about "Dompé Farmaceutici S.p.A." on BioPortfolio

We have published hundreds of Dompé Farmaceutici S.p.A. news stories on BioPortfolio along with dozens of Dompé Farmaceutici S.p.A. Clinical Trials and PubMed Articles about Dompé Farmaceutici S.p.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Dompé Farmaceutici S.p.A. Companies in our database. You can also find out about relevant Dompé Farmaceutici S.p.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...


Corporate Database Quicklinks



Searches Linking to this Company Record